These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 19243279)

  • 21. Targeting mTOR in Glioblastoma: Rationale and Preclinical/Clinical Evidence.
    Mecca C; Giambanco I; Donato R; Arcuri C
    Dis Markers; 2018; 2018():9230479. PubMed ID: 30662577
    [TBL] [Abstract][Full Text] [Related]  

  • 22. New paradigms in anticancer therapy: targeting multiple signaling pathways with kinase inhibitors.
    Faivre S; Djelloul S; Raymond E
    Semin Oncol; 2006 Aug; 33(4):407-20. PubMed ID: 16890796
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Combined expressional analysis, bioinformatics and targeted proteomics identify new potential therapeutic targets in glioblastoma stem cells.
    Stangeland B; Mughal AA; Grieg Z; Sandberg CJ; Joel M; Nygård S; Meling T; Murrell W; Vik Mo EO; Langmoen IA
    Oncotarget; 2015 Sep; 6(28):26192-215. PubMed ID: 26295306
    [TBL] [Abstract][Full Text] [Related]  

  • 24. miR128-1 inhibits the growth of glioblastoma multiforme and glioma stem-like cells via targeting BMI1 and E2F3.
    Shan ZN; Tian R; Zhang M; Gui ZH; Wu J; Ding M; Zhou XF; He J
    Oncotarget; 2016 Nov; 7(48):78813-78826. PubMed ID: 27705931
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Targeting cancer stem cells in glioblastoma multiforme using mTOR inhibitors and the differentiating agent all-trans retinoic acid.
    Friedman MD; Jeevan DS; Tobias M; Murali R; Jhanwar-Uniyal M
    Oncol Rep; 2013 Oct; 30(4):1645-50. PubMed ID: 23877261
    [TBL] [Abstract][Full Text] [Related]  

  • 26. MiR-203 downregulation is responsible for chemoresistance in human glioblastoma by promoting epithelial-mesenchymal transition via SNAI2.
    Liao H; Bai Y; Qiu S; Zheng L; Huang L; Liu T; Wang X; Liu Y; Xu N; Yan X; Guo H
    Oncotarget; 2015 Apr; 6(11):8914-28. PubMed ID: 25871397
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The Role of EGFR-Met Interactions in the Pathogenesis of Glioblastoma and Resistance to Treatment.
    Guo G; Narayan RN; Horton L; Patel TR; Habib AA
    Curr Cancer Drug Targets; 2017; 17(3):297-302. PubMed ID: 28004613
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Use of APO2L/TRAIL with mTOR inhibitors in the treatment of glioblastoma multiforme.
    Panner A; Parsa AT; Pieper RO
    Expert Rev Anticancer Ther; 2006 Sep; 6(9):1313-22. PubMed ID: 17020463
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Therapeutic advances in the treatment of glioblastoma: rationale and potential role of targeted agents.
    Reardon DA; Wen PY
    Oncologist; 2006 Feb; 11(2):152-64. PubMed ID: 16476836
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The role of STAT3 in glioblastoma progression through dual influences on tumor cells and the immune microenvironment.
    Chang N; Ahn SH; Kong DS; Lee HW; Nam DH
    Mol Cell Endocrinol; 2017 Aug; 451():53-65. PubMed ID: 28089821
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Disruption of parallel and converging signaling pathways contributes to the synergistic antitumor effects of simultaneous mTOR and EGFR inhibition in GBM cells.
    Rao RD; Mladek AC; Lamont JD; Goble JM; Erlichman C; James CD; Sarkaria JN
    Neoplasia; 2005 Oct; 7(10):921-9. PubMed ID: 16242075
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Revisiting CDK Inhibitors for Treatment of Glioblastoma Multiforme.
    Lubanska D; Porter L
    Drugs R D; 2017 Jun; 17(2):255-263. PubMed ID: 28324583
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A combination of tyrosine kinase inhibitors, crizotinib and dasatinib for the treatment of glioblastoma multiforme.
    Nehoff H; Parayath NN; McConnell MJ; Taurin S; Greish K
    Oncotarget; 2015 Nov; 6(35):37948-64. PubMed ID: 26517812
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Genetic and signaling pathway alterations in glioblastoma: relevance to novel targeted therapies.
    Rao RD; Uhm JH; Krishnan S; James CD
    Front Biosci; 2003 May; 8():e270-80. PubMed ID: 12700121
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Erlotinib: early clinical development in brain cancer.
    Addeo R; Zappavigna S; Parlato C; Caraglia M
    Expert Opin Investig Drugs; 2014 Jul; 23(7):1027-37. PubMed ID: 24836441
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The endoplasmic reticulum stress/unfolded protein response in gliomagenesis, tumor progression and as a therapeutic target in glioblastoma.
    Peñaranda Fajardo NM; Meijer C; Kruyt FA
    Biochem Pharmacol; 2016 Oct; 118():1-8. PubMed ID: 27106078
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Insulin-like growth factor receptor I mediates resistance to anti-epidermal growth factor receptor therapy in primary human glioblastoma cells through continued activation of phosphoinositide 3-kinase signaling.
    Chakravarti A; Loeffler JS; Dyson NJ
    Cancer Res; 2002 Jan; 62(1):200-7. PubMed ID: 11782378
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Genomic profiling of a Hepatocyte growth factor-dependent signature for MET-targeted therapy in glioblastoma.
    Johnson J; Ascierto ML; Mittal S; Newsome D; Kang L; Briggs M; Tanner K; Marincola FM; Berens ME; Vande Woude GF; Xie Q
    J Transl Med; 2015 Sep; 13():306. PubMed ID: 26381735
    [TBL] [Abstract][Full Text] [Related]  

  • 39. PDGF receptor alpha inhibition induces apoptosis in glioblastoma cancer stem cells refractory to anti-Notch and anti-EGFR treatment.
    Cenciarelli C; Marei HE; Zonfrillo M; Pierimarchi P; Paldino E; Casalbore P; Felsani A; Vescovi AL; Maira G; Mangiola A
    Mol Cancer; 2014 Nov; 13():247. PubMed ID: 25380967
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A Rationale for Targeting Extracellular Regulated Kinases ERK1 and ERK2 in Glioblastoma.
    Hannen R; Hauswald M; Bartsch JW
    J Neuropathol Exp Neurol; 2017 Oct; 76(10):838-847. PubMed ID: 28922853
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.